Windtree Therapeutics Stock Today

WINT Stock  USD 0.51  0.04  8.51%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 80

 
High
 
Low
High
Windtree Therapeutics is selling for under 0.51 as of the 22nd of November 2024; that is 8.51 percent increase since the beginning of the trading day. The stock's last reported lowest price was 0.49. Windtree Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Windtree Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
8th of August 1995
Category
Healthcare
Classification
Health Care
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Windtree Therapeutics, Inc. is a subsidiary of Lees Pharmaceutical Holdings Limited. The company has 8.75 M outstanding shares of which 195.67 K shares are at this time shorted by private and institutional investors with about 0.06 trading days to cover. More on Windtree Therapeutics

Moving together with Windtree Stock

  0.83VALN Valneva SE ADRPairCorr

Moving against Windtree Stock

  0.54KZR Kezar Life SciencesPairCorr
  0.54MLYS Mineralys Therapeutics,PairCorr
  0.45NXGLW NexGel WarrantPairCorr

Windtree Stock Highlights

President CEO, DirectorCraig Fraser
Old NameWest International AB (publ)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00140.0015
Notably Down
Pretty Stable
Total Current Liabilities3.8 MM
Notably Down
Slightly volatile
Non Current Liabilities Total14.1 M25 M
Way Down
Slightly volatile
Total Assets42.3 M32.4 M
Significantly Up
Slightly volatile
Total Current Assets5.1 M5.4 M
Notably Down
Slightly volatile
Debt Levels
Windtree Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Windtree Therapeutics' financial leverage. It provides some insight into what part of Windtree Therapeutics' total assets is financed by creditors.
Liquidity
Windtree Therapeutics currently holds 16.83 M in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Windtree Therapeutics has a current ratio of 2.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Windtree Therapeutics' use of debt, we should always consider it together with its cash and equity.

Net Income

(21.31 Million)
Windtree Therapeutics (WINT) is traded on NASDAQ Exchange in USA. It is located in 2600 Kelly Road, Warrington, PA, United States, 18976-3622 and employs 12 people. Windtree Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.92 M. Windtree Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.75 M outstanding shares of which 195.67 K shares are at this time shorted by private and institutional investors with about 0.06 trading days to cover. Windtree Therapeutics currently holds about 11.38 M in cash with (13.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37.
Check Windtree Therapeutics Probability Of Bankruptcy
Ownership Allocation
Roughly 99.14 (%) of Windtree Therapeutics outstanding shares are held by general public with 0.27 % owned by insiders and only 0.59 percent by institutional investors.
Check Windtree Ownership Details

Windtree Stock Institutional Holders

InstituionRecorded OnShares
Tower Research Capital Llc2024-06-30
1.5 K
Bank Of America Corp2024-06-30
4.0
Ubs Group Ag2024-06-30
3.0
Activest Wealth Management2024-06-30
2.0
Ifp Advisors, Llc2024-06-30
1.0
View Windtree Therapeutics Diagnostics

Windtree Therapeutics Historical Income Statement

At this time, Windtree Therapeutics' Other Operating Expenses is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 28.8 M in 2024, whereas Gross Profit is likely to drop (86.1 K) in 2024. View More Fundamentals

Windtree Stock Against Markets

Windtree Therapeutics Corporate Executives

Elected by the shareholders, the Windtree Therapeutics' board of directors comprises two types of representatives: Windtree Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Windtree. The board's role is to monitor Windtree Therapeutics' management team and ensure that shareholders' interests are well served. Windtree Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Windtree Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Eric MBASenior COOProfile

Already Invested in Windtree Therapeutics?

The danger of trading Windtree Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Windtree Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Windtree Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Windtree Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Tools for Windtree Stock Analysis

When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.